3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
3
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Hepatoblastoma
1
Extensive Stage Lung Small Cell Carcinoma
1
Interventions
Dexamethasone
43
Lenalidomide
26
daratumumab
23
Bortezomib
23
pomalidomide
22
Cyclophosphamide
16
Specimen Handling
14
Biopsy
14
carfilzomib
13
Magnetic Resonance Spectroscopy
11
talquetamab
10
iberdomide
9
fludarabine
9
Calcium Dobesilate
9
isatuximab
8
Melphalan
8
belantamab mafodotin
7
selinexor
5
fludarabine phosphate
5
X-Rays
5
elotuzumab
4
Whole-Body Irradiation
4
Nuclear Medicine Department, Hospital
4
trametinib
3
tocilizumab
3
dexamethasone acetate
3
dexamethasone 21-phosphate
3
dabrafenib
3
auricularum
3
Thalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
talazoparib
×
30 days
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled